Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria

BACKGROUND: The administration of calcineurin inhibitors (CNIs) posttransplant has been implicated as an independent risk factor for the recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT). The new immunosuppressive agent sirolimus (SRL) acts as a primary immunosuppressant...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Transl Med
Main Authors: Ling, Sunbin, Feng, Tingting, Zhan, Qifan, Duan, Xin, Jiang, Guangjiang, Shen, Tian, Shan, Qiaonan, Xu, Shengjun, Ye, Qianwei, Liu, Peng, Cen, Beini, Zheng, Shusen, Xu, Xiao
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049005/
https://ncbi.nlm.nih.gov/pubmed/32175373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2020.01.10
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados